Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

7.84USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$7.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
59,092
52-wk High
$8.33
52-wk Low
$1.93

CCXI.OQ

Chart for CCXI.OQ

About

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $388.66
Shares Outstanding(Mil.): 47.81
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -0.97 -- --
ROI: -46.37 15.56 14.95
ROE: -64.59 16.69 16.29

BRIEF-Chemocentryx reports Q3 loss per share $0.15

* Chemocentryx reports third quarter 2016 financial results and provides corporate update

Nov 07 2016

BRIEF-Chemocentryx reports presentation of positive data from ongoing pilot phase II trial of CCX168

* Chemocentryx announces presentation of positive data from ongoing pilot phase II trial of CCX168 (avacopan) in atypical hemolytic uremic syndrome (AHUS) at ASN kidney week 2016

Oct 17 2016

BRIEF-ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872

* Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer

Sep 01 2016

Earnings vs. Estimates